Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis

Journal: Science Translational Medicine

Published: 2019-10-30

DOI: 10.1126/scitranslmed.aau6296

Affiliations: 10

Authors: 25

Go to article
Institutions Share
Mayo Clinic Department of Physiology and Biomedical Engineering, United States of America (USA) 0.49
Mayo Clinic Division of Gastroenterology and Hepatology (GIH), United States of America (USA) 0.12
Division of Pulmonary, Allergy, and Critical Care Medicine (PACCM), Pitt, United States of America (USA) 0.08
UPMC Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, United States of America (USA) 0.08
Mayo Clinic Department of Anesthesiology and Perioperative Medicine, United States of America (USA) 0.05
Mayo Clinic Department of Laboratory Medicine and Pathology (DLMP), United States of America (USA) 0.04
Center for Immunology and Inflammatory Diseases (CIID), MGH, United States of America (USA) 0.04
Adult Cystic Fibrosis Center, MGH, United States of America (USA) 0.04
Department of Biochemistry, BU, United States of America (USA) 0.04
Abigail Wexner Research Institute, Nationwide Children's Hospital, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER